Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Transl Psychiatry ; 5: e567, 2015 May 19.
Artigo em Inglês | MEDLINE | ID: mdl-25989141

RESUMO

Self-injurious behavior (SIB) is a common comorbidity of psychiatric disorders but there is a dearth of information about neurological mechanisms underlying the behavior, and few animal models exist. SIB in humans is characterized by any intentional self-directed behavior that leads to wounds, whereas in macaques it is not always accompanied by wounds. We describe a cohort of rhesus macaques displaying SIB as adults, in which changes within the central nervous system were associated with the SIB. In these macaques, increases in central nervous system striatal dopamine (DA) receptor binding (BPND) measured by positron emission tomography (PET) [11C]raclopride imaging correlated with severity of wounding (rs=0.662, P=0.014). Furthermore, utilizing standardized cognitive function tests, we showed that impulsivity (stop signal reaction time, SSRT) and deficits in attentional set shifting (intra-/extradimensional shift) were correlated with increased severity of SIB (rs=0.563, P=0.045 and rs=0.692, P=0.009, respectively). We also tested the efficacy of guanfacine, an α2A adrenergic agonist that acts to improve postsynaptic transmission of neuronal impulses, in reducing SIB. A subset of these animals were enrolled in a randomized experimenter-blinded study that demonstrated guanfacine decreased the severity of wounding in treated animals compared with vehicle-only-treated controls (P=0.043), with residual beneficial effects seen for several weeks after cessation of therapy. Animals with the highest severity of SIB that received guanfacine also showed the most significant improvement (rs=-0.761, P=0.009). The elevated PET BPND was likely due to low intrasynaptic DA, which in turn may have been improved by guanfacine. With underlying physiology potentially representative of the human condition and the ability to affect outcome measures of disease using pharmacotherapy, this model represents a unique opportunity to further our understanding of the biology and treatment of SIB in both animals and humans.


Assuntos
Agonistas de Receptores Adrenérgicos alfa 2/farmacologia , Comportamento Animal/efeitos dos fármacos , Transtornos Cognitivos/fisiopatologia , Guanfacina/farmacologia , Comportamento Impulsivo/efeitos dos fármacos , Neostriado/diagnóstico por imagem , Receptores Dopaminérgicos/metabolismo , Comportamento Autodestrutivo/fisiopatologia , Agonistas de Receptores Adrenérgicos alfa 2/uso terapêutico , Animais , Atenção/fisiologia , Radioisótopos de Carbono , Cognição/fisiologia , Modelos Animais de Doenças , Antagonistas de Dopamina , Guanfacina/uso terapêutico , Comportamento Impulsivo/fisiologia , Macaca mulatta , Masculino , Neostriado/metabolismo , Neostriado/fisiopatologia , Testes Neuropsicológicos , Tomografia por Emissão de Pósitrons , Racloprida , Distribuição Aleatória , Tempo de Reação , Comportamento Autodestrutivo/tratamento farmacológico , Índice de Gravidade de Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...